34
Participants
Start Date
September 12, 2011
Primary Completion Date
September 20, 2017
Study Completion Date
September 20, 2017
Gynaecological follow-up
Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
Cervarix
Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
Placebo control
Subjects received 3 doses of the control \[Al(OH)3\] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
GSK Investigational Site, Iowa City
GSK Investigational Site, Wichita
GSK Investigational Site, Wenatchee
GSK Investigational Site, Moscow
GSK Investigational Site, Singapore
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Singapore
GSK Investigational Site, Edmonton
GSK Investigational Site, Vancouver
GSK Investigational Site, Halifax
GSK Investigational Site, Truro
GSK Investigational Site, Sherbrooke
GSK Investigational Site, Amsterdam
GSK Investigational Site, Rotterdam
GSK Investigational Site, Almada
GSK Investigational Site, Coimbra
GSK Investigational Site, Lisbon
GSK Investigational Site, Setúbal
GSK Investigational Site, London
GSK Investigational Site, Manchester
Lead Sponsor
GlaxoSmithKline
INDUSTRY